Vivos Therapeutics (VVOS) Proxy filing summary

Executive summary

• Annual meeting set for Dec. 2, 2026, at 10:00 a.m. MST; voting instructions must be received by Dec. 1, 2026.

• Ballot covers seven director elections and Proposals 2–10, including executive pay, auditor ratification, capital issuances, a reverse split, equity-plan expansion, and conversion to Nevada.

Voting matters and shareholder proposals

• Board recommends FOR advisory approval of named executive officer compensation and recommends future say-on-pay votes every 3 years.

• Proposal 10 seeks authority to adjourn the meeting if needed to solicit votes for Proposals 5–9.

• Shareholders may provide voting instructions online, by phone, mail, or in person; unmarked items on a signed, returned form follow board recommendations.

Board of directors and corporate governance

• Board recommends FOR election of R. Kirk Huntsman, Ralph E. Green, Anja Krammer, Mark F. Lindsay, Leonard J. Sokolow, Matthew Thompson, and Gregg C. E. Johnson.

• Proposal 9 seeks approval to convert from a Delaware to a Nevada corporation, including the conversion plan, Nevada articles, and bylaws.